Literature DB >> 11460477

Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2).

H Ritchie1, L C Lawrie, M W Mosesson, N A Booth.   

Abstract

PAI-2 is a serpin that can be crosslinked to fibrin(ogen) via the Gln-Gln-Ile-Gln sequence (residues 83-86). We have characterized the lysine residues in fibrinogen to which PAI-2 is crosslinked by tissue transglutaminase and factor XIIIa. There was no competition with the crosslinking of alpha 2-antiplasmin, another inhibitor of fibrinolysis, which was specific for Lys 303 in the A alpha chain. PAI-2 was crosslinked to several lysine residues, all in the A alpha chain, 148, 176, 183, 230, 413, and 457, but not to Lys 303. The contrast with alpha 2-antiplasmin was clear from studies with truncated fibrinogens and competition by peptides. This was confirmed and extended by mass spectrometry of peptides after protease digestion of crosslinked products, which identified the lysine residues to which the inhibitors were crosslinked. PAI-2 remained active after cross-linking and inhibited fibrin breakdown, even by two-chain t-PA. Thus, a second inhibitor of fibrinolysis, in addition to alpha 2-antiplasmin, is crosslinked to fibrin and protects it from lysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11460477     DOI: 10.1111/j.1749-6632.2001.tb03508.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Ranking reactive glutamines in the fibrinogen αC region that are targeted by blood coagulant factor XIII.

Authors:  Kelly Njine Mouapi; Jacob D Bell; Kerrie A Smith; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  Blood       Date:  2016-03-07       Impact factor: 22.113

Review 2.  Fibrinogen αC domain: Its importance in physiopathology.

Authors:  Jeannette Soria; Shahsoltan Mirshahi; Sam Qiumars Mirshahi; Remi Varin; Linda L Pritchard; Claudine Soria; Massoud Mirshahi
Journal:  Res Pract Thromb Haemost       Date:  2019-02-15

Review 3.  Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.

Authors:  Vassilios P Memtsas; Deepa R J Arachchillage; Diana A Gorog
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

Review 4.  Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.

Authors:  Nikoletta Pechlivani; Katherine J Kearney; Ramzi A Ajjan
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

Review 5.  Inhibition of Fibrinolysis by Coagulation Factor XIII.

Authors:  Dingeman C Rijken; Shirley Uitte de Willige
Journal:  Biomed Res Int       Date:  2017-07-06       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.